We reviewed 2019’s top developments in Canadian life sciences IP and regulatory law in our highlights article. Below were our top 10 reads:
#1 Update on biosimilars in Canada – October 2019
#4 Canada releases final amendments to Patented Medicines Pricing Regulations; in force July 1, 2020
#6 Amended PMNOC Regulations: Second Anniversary Update
#7 Federal Court issues two interlocutory decisions in section 8 pregabalin case
#8 Orders of prohibition relating to polymorphic form patent for PRISTIQ upheld on appeal
#9 Federal Court of Appeal confirms obviousness finding in section 8 bortezomib action against Teva
Related Publications & Articles
-
Twice is not nice – second notice of allegation may be abusive
On December 23, 2023, the Federal Court of Appeal (FCA) held that it was an abuse of process for Apotex to raise invalidity in defending actions under the Patented Medicines (Notice of Compliance) Reg...Read More -
FCA upholds inducement of infringement findings relating to paliperidone palmitate
On January 12, 2024, the Federal Court of Appeal (FCA) dismissed both appeals: Apotex Inc v Janssen Inc, 2024 FCA 9 and Pharmascience Inc v Janssen Inc, 2024 FCA 10.Read More -
Update on biosimilars in Canada – March 2024
In this article, we provide a further update on developments regarding biosimilars in Canada (approvals, pending submissions, litigation, regulatory, and market access).Read More